Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
McKinsey
Merck

Last Updated: February 1, 2023

Patent: 10,099,009


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,099,009
Title:Central venous catheter with reverse flush port
Abstract: A catheter having a secondary port that enables flushing a fluid from a portion of the catheter. The secondary port is disposed along the length of the catheter tube so as to be near an entry point of the catheter into a patient\'s body. A clamp is disposed adjacent to the secondary port on a side proximate to the patient\'s body. The secondary port and clamp enable flushing of a fluid from a portion of the catheter that is external to the patient\'s body and disposal of a clot- or obstruction-dissolving agent into the external portion of the catheter. Upon removal of the clot or obstruction, the secondary port and clamp enable removal of the dissolving agent and replenishing the fluid in the external portion of the catheter to resume provision of the fluid to the patient.
Inventor(s): Anderson; Judith L. (Shawnee, KS)
Assignee:
Application Number:15/064,224
Patent Claims:see list of patent claims

Details for Patent 10,099,009

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Microbix Biosystems Inc. KINLYTIC urokinase For Injection 021846 01/16/1978 See Plans and Pricing 2035-03-12
Genentech, Inc. ACTIVASE alteplase For Injection 103172 11/13/1987 See Plans and Pricing 2035-03-12
Genentech, Inc. CATHFLO ACTIVASE alteplase For Injection 103172 09/04/2001 See Plans and Pricing 2035-03-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Harvard Business School
Medtronic
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.